New dual peroxisome proliferator activated receptor agonist —Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence

Saroglitazar, a novel dual peroxisome proliferator activated receptor (PPAR) agonist, in clinical trials, has shown an improvement in lipid and glycemic parameters through the PPAR- α and γ agonist actions, res...
Source: Cardiovascular Diabetology - Category: Cardiology Authors: Tags: Review Source Type: research

Related Links:

ConclusionExperimental validation of network analysis revealed anti-diabetic effects of the plant product SGD, manifested most notably by improved serum profiles and diminished insulin resistance. These experimental results may have clinical implications.Graphical abstract
Source: Journal of Ethnopharmacology - Category: Drugs & Pharmacology Source Type: research
In this issue of Metabolism, Omori et al [1] report that dapagliflozin, a sodium-glucose co-transporter-2 inhibitor (SGLT2i), prevents hepatic steatosis (assessed by triglyceride liver content) after 8  weeks of administration in db/db mice, a mouse model of obesity and diabetes.
Source: Metabolism - Clinical and Experimental - Category: Biomedical Science Authors: Source Type: research
In this study, the effects of AGE on fatty liver, insulin resistance and intestinal microbiota were compared between ddY-H mice, an insulin resistance mouse, and ddY-L mice, normal mice. Mice were fed an AGE-supplemented diet (4% w/w) for 7 weeks. The administration of AGE had no effect on the body weight and dietary intake of both types of mice. In the ddY-H mice, the serum levels of glucose and insulin were increased and glucose tolerance was impaired; however, the administration of AGE ameliorated these abnormal conditions. AGE did not have these effects in ddY-L mice. Triglyceride (TG) accumulation in the liver and fat...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
This article is protected by copyright. All rights reserved. PMID: 31278754 [PubMed - as supplied by publisher]
Source: The Journal of Physiology - Category: Physiology Authors: Tags: J Physiol Source Type: research
Molecules, Vol. 24, Pages 2479: The Modulatory Action of Vitamin D on the Renin–Angiotensin System and the Determination of Hepatic Insulin Resistance Molecules doi: 10.3390/molecules24132479 Authors: Po Sing Leung Vitamin D deficiency or hypovitaminosis D is associated with increased risks of insulin resistance, type 2 diabetes mellitus (T2DM) and its related non-alcoholic fatty liver disease (NAFLD). Meanwhile, inappropriate over-activation of the renin–angiotensin system (RAS) in the liver leads to the hepatic dysfunction and increased risk of T2DM, such as abnormalities in lipid and glucose meta...
Source: Molecules - Category: Chemistry Authors: Tags: Commentary Source Type: research
With the growing prevalence of childhood obesity, pediatric non-alcoholic fatty liver disease (NAFLD) has emerged as the most common chronic liver disease in children and adolescents in Western countries [1 –3]. NAFLD is a spectrum of progressive liver disease that encompasses simple steatosis, non-alcoholic steatohepatitis (NASH), advanced fibrosis and, ultimately, cirrhosis [3,4]. Compelling evidence indicates that NAFLD also has serious health consequences outside of the liver and is strongly asso ciated with an increased risk of cardiovascular disease and abnormal glucose tolerance (prediabetes and type 2 diabetes) [5–7].
Source: Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide, with a global prevalence of 25.2% [1]. NAFLD is defined by the presence of hepatic steatosis, detected either by imaging or histology, and a lack of secondary causes of hepatic fat accumulation (i.e. excessive alcohol consumption, steatogenic medication, or monogenic hereditary disorders) [2].
Source: Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research
Source: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy - Category: Endocrinology Tags: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Source Type: research
Conditions:   Non-Alcoholic Fatty Liver Disease;   Obesity;   Pre-diabetes Interventions:   Other: Alternate day fasting;   Other: Exercise Sponsor:   University of Illinois at Chicago Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
[Microbiome &NASH - partners in crime driving progression of fatty liver disease]. Z Gastroenterol. 2019 Jul;57(7):871-882 Authors: Wree A, Geisler LJ, Tacke F Abstract Along with the increasing prevalence of obesity, metabolic syndrome and type 2 diabetes, non-alcoholic fatty liver disease (NAFLD) is rapidly increasing and poses a major challenge for gastroenterologists. Many studies have demonstrated that the microbiome is closely associated with the progression of nutrition-related diseases, especially of fatty liver disease. Changes in the quantity and quality of the intestinal flora, commonly...
Source: Zeitschrift fur Gastroenterologie - Category: Gastroenterology Authors: Tags: Z Gastroenterol Source Type: research
More News: Alcoholism | Cardiology | Cardiovascular | Clinical Trials | Diabetes | Endocrinology | Fatty Liver Disease (FLD) | Heart | Liver | Liver Disease | Non-alcoholic Fatty Liver Diseases (NAFLD) | Urology & Nephrology